**Andrea Fratter 1,2,\*, Vera Mason 1, Marzia Pellizzato 1, Stefano Valier 3, Arrigo Francesco Giuseppe Cicero 4, Erik Tedesco 5, Elisa Meneghetti <sup>5</sup> and Federico Benetti <sup>5</sup>**


Received: 6 January 2019; Accepted: 31 January 2019; Published: 4 February 2019

**Abstract:** The class of lipophilic compounds coming from vegetal source represents a perspective in the adjuvant treatment of several human diseases, despite their poor bioavailability in humans. These compounds are generally soluble in fats and poorly soluble in water. The major reason for the poor bioavailability of lipophilic natural compounds after oral uptake in humans is related to their reduced solubility in enteric water-based fluids, leading to an ineffective contact with absorbing epithelium. The main goal to ensure efficacy of such compounds is then creating technological conditions to deliver them into the first enteric tract as hydro-dispersible forms to maximize epithelial absorption. The present work describes and characterizes a new technological matrix (Lipomatrix, Labomar Research, Istrana, TV, Italy) based on a molten fats core in which Ascorbyl Palmitate is embedded, able to deliver lipophilic compounds in a well-dispersed and emulsified form once exposed to duodenal fluids. Authors describe and quantify Lipomatrix delivery of *Serenoa repens* oil through an innovative in vitro model of human gastro-enteric digestion, reporting results of its improved bioaccessibility, enteric absorption and efficacy compared with not formulated *Serenoa repens* oil-containing commercial products using in vitro models of human intestine and prostatic tissue.

**Keywords:** ascorbyl palmitate; mono and diglycerides of fatty acids; natural lipophilic compounds; nutraceutical products; *Serenoa repens* oil; enteric bioaccessibility
